NCT04993157View on ClinicalTrials.gov

Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

June 28, 2022

Study Completion Date

June 28, 2022

Conditions
Hepatic Impairment
Interventions
DRUG

FIA586

FIA586 capsule

Trial Locations (2)

32809

Novartis Investigative Site, Orlando

33124

Novartis Investigative Site, Coral Gables

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY